Background: Recent breast cancer treatment guidelines recommend that higher-risk premenopausal patients should receive ovarian function suppression (OFS) as part of adjuvant endocrine therapy. If chemotherapy is also given, it is uncertain whether to select concurrent or sequential OFS initiation.
Introduction
Surgical ovarian ablation was the first systemic adjuvant treatment of breast cancer [1] . More recently, gonadotropin-releasinghormone (GnRH) agonists provide a reversible method to achieve ovarian function suppression (OFS). Several trials have since compared ovarian ablation or GnRH-agonist-induced OFS to chemotherapy alone and/or with chemotherapy followed by OFS in premenopausal women with hormone receptor-positive (HRþ) early breast cancer (with or without oral endocrine therapy) [2] . However, addition of OFS to endocrine adjuvant treatment of HRþ breast cancer has remained controversial for a number of reasons, including the confounding effect of chemotherapyinduced amenorrhea (CIA) and study designs including non-HRþ patients and omitting a tamoxifen-alone comparator. Current anthracycline/taxane-based regimens are associated with a lower incidence of CIA than older alkylating-based regimens such as cyclophosphamide/methotrexate/5-fluorouracil, especially in younger women [3] . Data from 9864 premenopausal patients treated with chemotherapy alone in cooperative group trials showed a significantly worse outcome for very young patients (<35 years) with HRþ tumors compared with older HRþ patients [4] . The age-related difference in outcome was much smaller for HR-negative patients. The lower incidence of CIA in very young patients translates into an attenuated endocrine effect of chemotherapy and suggests a potential impact of early initiation of adjuvant endocrine therapy [4, 5] .
There are theoretical concerns about the concurrent use of endocrine therapy with chemotherapy based on laboratory and animal studies [6] [7] [8] . The only randomized evidence in the adjuvant setting derives from studies in postmenopausal women treated with tamoxifen [9] [10] [11] . The data for concurrent use of endocrine therapy and chemotherapy in premenopausal women are scanty: among 1096 patients (39% premenopausal) enrolled in two trials of adjuvant chemotherapy, in which tamoxifen was given concomitantly or sequentially by physician discretion, no difference in DFS was reported [12] . Subgroup analyses suggested greater benefit of concomitant versus sequential therapy among 427 premenopausal women, particularly those aged 40 years [12] . However, concomitant tamoxifen does increase the risk of thrombotic events during chemotherapy and is not recommended [11] .
The TEXT and SOFT randomized phase III trials studied adjuvant endocrine therapy for premenopausal women with HRþ early breast cancer [13] [14] [15] . TEXT enrolled patients before starting any adjuvant therapy, including chemotherapy, whereas SOFT enrolled patients who were premenopausal after finishing adjuvant chemotherapy. Thus the timing of OFS and chemotherapy, if chemotherapy was given, differed in the two trials, being concurrent in TEXT and sequential in SOFT. Based largely on the results of SOFT and TEXT, guidelines recommend higher-risk patients should receive OFS as part of adjuvant endocrine therapy [16] [17] [18] [19] .
Several questions remain. Is there a best timing for initiating OFS when chemotherapy is also given? Is there a benefit to undergoing OFS as quickly as possible, concurrently with chemotherapy, or might concurrent administration be detrimental? Is it equivalent to wait and see if chemotherapy induces menopause thereby avoiding GnRH-agonist injections? Should age be taken into consideration when deciding when to start OFS? In the absence of a randomized clinical trial to address these questions, we used comparative-effectiveness methods for non-randomized treatment comparisons to conduct an exploratory, observational study of SOFT/TEXT patients treated with adjuvant chemotherapy and GnRH-agonist. We investigated whether there was evidence of differential efficacy between initiating adjuvant GnRH-agonist concurrently with chemotherapy versus sequentially after chemotherapy, once premenopausal status was reestablished.
Patients and methods
The designs and conduct of the TEXT/SOFT trials have been described previously [13] [14] [15] . The ethics committee at each participating center approved the study protocols; all patients provided written informed consent. In both trials, eligible premenopausal women had surgically resected, invasive early HRþ breast cancer (!10% ER and/or PgRexpressing cells). Endocrine therapy, including OFS if it was assigned, was given for 5 years; oral endocrine therapy commenced after chemotherapy in both trials.
In TEXT, OFS was given from the start of adjuvant therapy. Between November 2003 and March 2011, 2660 women were randomized within 12 weeks after definitive surgery to exemestane þ OFS or tamoxifen þ OFS. OFS was by GnRH-agonist triptorelin; after at least 6 months of triptorelin, patients could opt for ovarian ablation. Chemotherapy was optional and planned for 1607 (60%) patients, started concurrently with triptorelin.
In SOFT, OFS was given sequentially after chemotherapy. Between December 2003 and January 2011, 3047 women were randomized to tamoxifen, tamoxifen þ OFS or exemestane þ OFS. A total of 1628 (53%) patients who received prior (neo)adjuvant chemotherapy were randomized within 8 months after the final dose of chemotherapy once a premenopausal level of estradiol was confirmed. Use of triptorelin or ovarian ablation, if OFS was assigned, was by patient preference.
Analysis population, endpoints and statistical considerations
In the intention-to-treat populations, 2693 patients within the chemotherapy strata were randomized to an OFS-containing combination. After exclusions, 1320 patients from TEXT and 654 from SOFT with HER2-negative disease treated with adjuvant chemotherapy and triptorelin were analyzed (Figure 1 ). TEXT patients were enrolled a median of 1.8 months post-surgery. SOFT patients were enrolled after adjuvant chemotherapy, after demonstration of premenopausal estradiol level, at a median of 9.8 months post-surgery. To avoid guarantee-time bias, the observation periods for analysis were re-aligned forwards, by defining a landmark time point at 1 year after the final dose of chemotherapy, which ensured that all SOFT patients could have reached the first 3-month protocol visit (supplementary Figure S1 , available at Annals of Oncology online). Among TEXT and SOFT patients, the landmark was a median of 15.5 months [interquartile range (IQR) 14.3-16.0 months] and 8.1 months (IQR 6.3-9.8 months) post-enrollment.
The primary endpoint was breast cancer-free interval (BCFI), defined as the time interval beginning 1 year after final dose of adjuvant chemotherapy until the first appearance of invasive local-regional or distant recurrence or invasive contralateral breast cancer; in the absence of an event, BCFI was censored at date of last visit (or date of death without breast cancer event). The secondary endpoint was distant recurrence-free interval (DRFI), similarly defined beginning 1 year after final dose of adjuvant chemotherapy until the first appearance of invasive distant recurrence. BCFI was the chosen endpoint, rather than DFS, to disregard second (non-breast) invasive malignancies that occurred at similar frequencies across treatment groups.
Because timing of triptorelin initiation with chemotherapy was not randomized and there were differences in patient characteristics and prognostic features between TEXT and SOFT patients, the analysis used an inverse probability of 'treatment' weighting (IPTW) analysis using a propensity score [20] . The propensity score for the probability of concurrent versus sequential triptorelin (i.e. TEXT versus SOFT enrollment), conditional on measured patient, disease and treatment covariates, used logistic regression (supplementary Table S1 , available at Annals of Oncology online). The covariates were pre-specified as those believed to be prognostic and potentially associated with enrollment into the trials, without use of variable-selection procedures [20] , as presented in Table 1 . The primary analysis used age at diagnosis; as sensitivity analysis, the analysis was repeated using age at enrollment (supplementary data, available at Annals of Oncology online). We calculated average treatment effect in the 'treated' (ATT) weights referenced to the TEXT population with concurrent triptorelin and used absolute standardized differences in characteristics between groups as diagnostic tool [21] (supplementary  Table S2 , available at Annals of Oncology online). An IPTW log-rank test and IPTW Kaplan-Meier estimates of time-to-event were estimated [22] , as well as hazard ratios (HR) with 95% confidence intervals from an IPTW Cox model using robust standard errors.
Results
The eligible population included 1320 HRþ/HER2-negative premenopausal patients who initiated triptorelin concurrently with chemotherapy in TEXT (concurrent), and 654 premenopausal patients who initiated triptorelin after adjuvant chemotherapy in SOFT (sequential; Figure 1 ). The estimated 5-year BCFI was 88.6% (61.0%) and 86.4% (61.4%) among TEXT and SOFT patients, respectively, based on data from time of trial enrollment (i.e. before introducing landmark and IPTW analyses). After introducing the landmark analysis, the final analysis population included 1872 patients who remained alive, disease-free and in follow-up at the landmark of 1 year since the final dose of Differences between the two groups were evident in most characteristics. In particular, SOFT patients receiving sequential triptorelin were younger than TEXT patients receiving concurrent triptorelin (median age at diagnosis 39 and 43 years, respectively). The median duration of adjuvant chemotherapy was 18 weeks (IQR 12-18 weeks) in both groups. At the landmark time point, 85% of concurrent and 87% of sequential patients continued triptorelin, 11% and 8% had undergone ovarian ablation, respectively, and 5% had ceased OFS early. In total 93% of patients continued the assigned oral endocrine therapy (91% and 95%, respectively).
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There were 231 (12%) breast cancer events in the 2 groups at post-landmark median follow-up of 4.7 and 4.9 years. The concurrent use of triptorelin with chemotherapy was not associated with a significant difference in BCFI (HR ¼ 1.11, 95% CI 0.72-1.72; p ¼ 0.72), with an estimated 89.1% (61.0%) and 89.0% (62.9%) patients breast cancer-free at 4 years post-landmark, with concurrent and sequential triptorelin initiation, respectively ( Figure 2) . The results were similar for DRFI; 187 distant recurrences were reported, with estimated 90.8% (60.9%) and 90.5% (62.7%) patients distant recurrence-free in the concurrent and sequential groups, respectively, at 4 years post-landmark (HR ¼ 0.96, 95% CI 0.60-1.53; p ¼ 0.86).
There was no evidence of differential effectiveness of concurrent triptorelin among younger women (<40 years at diagnosis; n ¼ 692) than older premenopausal women at this point in follow-up (Figure 3 ). The estimated BCFI at 4 years postlandmark with concurrent and sequential triptorelin, respectively, was 84.8% (62.0%) and 82.9% (63.5%) for women aged <40 years at diagnosis (HR ¼ 1.13, 95% CI 0.69-1.84), and 90.8% (61.1%) and 91.7% (63.4%) for those !40 years at diagnosis (HR ¼ 1.10, 95% CI 0.57-2.14).
Discussion
TEXT and SOFT demonstrated the benefit of adding OFS to tamoxifen alone in high-risk patients remaining premenopausal after Absolute standardized difference is the absolute value of the difference in sample proportions of the two groups divided by the pooled standard deviation. a Prior endocrine therapy was allowed in SOFT but not TEXT. Among the 284 patients, the median duration of prior tamoxifen was 17 weeks (interquartile range, 10-23 weeks). BMI, body mass index; ER, estrogen receptor; PR, progesterone receptor; BCS, breast-conserving surgery; RT, radiotherapy; OFS, ovarian function suppression.
adjuvant chemotherapy and of exemestane over tamoxifen when combined with OFS. When chemotherapy was also given, OFS initiation differed between TEXT and SOFT (concurrently or sequentially with chemotherapy, respectively) to accommodate different attitudes worldwide. The trials were not designed to elucidate an optimal strategy. The sequential administration, by postponing an effective targeted therapy in premenopausal patients at higher-risk of relapse, might reduce treatment efficacy. On the other hand, the concurrent strategy might interfere with the cytotoxic activity of chemotherapy and will mask and abrogate the therapeutic role of CIA, especially in older premenopausal women, resulting in 5 years of potentially unnecessary and costly GnRH-agonist therapy. To investigate this relevant clinical issue, we analyzed 1872 patients with HER2-negative breast cancer who received adjuvant triptorelin in SOFT/TEXT. Our analysis showed no difference in the BCFI between the concurrent and sequential triptorelin treatment groups, neither overall nor in the subgroup of women <40 years at diagnosis who are less likely to develop CIA, after about 5-years median follow-up. Timing and sequencing of endocrine therapy and chemotherapy has not been adequately studied in early breast cancer [23] . The biologic evidence relates to tamoxifen, which works by a different endocrine mechanism than OFS [7, 24] . The tamoxifeninduced blockade in the G1-S phase of the cell cycle has been hypothesized to antagonize the antitumor effect of chemotherapy. The 2011 Early Breast Cancer Trialists' Collaborative Group (EBCTCG) overview of adjuvant tamoxifen showed significant recurrence risk (RR) reduction regardless of its concurrent (RR ¼ 0.62) or sequential (RR ¼ 0.71) administration with chemotherapy [25] . A small number of neoadjuvant studies compared sequential chemotherapy followed by OFS to concurrent therapy. The NSABP B-52 trial, in which 46% of patients were premenopausal, recently showed that adding endocrine therapy (GnRH-agonist þ AI) to neoadjuvant immunochemotherapy in HRþ/HER2-positive breast cancer was not antagonistic and did not increase toxicity [26] . The only large trials studying OFS concurrently with chemotherapy assessed ovarian/fertility preservation, but the majority were restricted to HR-negative breast cancer [27] . Reassuringly, the breast cancer outcomes have not been compromised by the addition of concomitant GnRH-agonist [27] .
Our analysis has limitations, mainly its non-randomized nature and the planned difference in enrollment timing in SOFT and TEXT, which led to inherent differences in the populations. Despite the use of IPTW and landmark analysis to balance the characteristics between concurrent and sequential OFS groups and align the periods of observation as in a randomized trial, the methodology may not have adequately overcome these issues. Moreover, median follow-up for SOFT/TEXT was <6 years, and differences in concurrent versus sequential OFS and chemotherapy could appear only later in follow-up. Statistical power was limited, especially for the subgroup <40 years, and real differences between the strategies may not have been detected.
From a clinical perspective, as no randomized trial will be conducted to properly answer this question, when chemotherapy will also be given, clinicians and patients need to select the concurrent or sequential strategy of OFS on an individual basis. Which considerations may help in guiding this decision? Concurrent administration does not increase chemotherapy-related adverse events [15] and the possibility to avoid permanent menopause and its consequences is attractive for younger premenopausal women. The rate of CIA is age-and regimen-dependent: most very young women (<35 years) resume menses after chemotherapy and could consider concurrent OFS thus receiving and completing a therapy that has proved to be particularly effective in this age group [14] 6 months earlier. In premenopausal women, the possibility to preserve fertility in addition to the adjuvant effect is especially attractive for those not having completed family planning. In contrast, in women already approaching menopause, delaying GnRH-agonist administration until resumption of menses after chemotherapy may avoid unnecessary and costly drug administration. For women on tamoxifen following chemotherapy, the evaluation of ovarian function can be challenging, especially in patients developing amenorrhea [28] . SOFT/TEXT data represent the only evidence available in premenopausal patients from a large sample within controlled clinical trials: they support clinicians and patients selecting the concurrent or sequential strategy of chemotherapy and OFS on an individual patient basis.
